Literature DB >> 8557681

Characterization of an unusual Rho factor from the high G + C gram-positive bacterium Micrococcus luteus.

W L Nowatzke1, J P Richardson.   

Abstract

A transcription termination factor (Rho) was purified from the Gram-positive bacterium Micrococcus luteus, and the complete gene sequence was determined. The M. luteus Rho polypeptide has 690 residues, which is 271 residues more than its homolog from Escherichia coli. Most of the additional residues compose a highly charged, hydrophilic segment that is inserted in a non-conserved region between two conserved regions of the RNA-binding domain of the known Rho homolog proteins. This segment extends from residues 49 to 311 and includes a stretch of 238 residues that contain no hydrophobic side chains. Biochemical studies indicate that the M. luteus protein is very similar to E. coli Rho in terms of its RNA-dependent NTPase activity and its sensitivity to the Rho-specific inhibitor bicyclomycin. However, the M. luteus protein has a less stringent RNA cofactor specificity. It also acts to terminate RNA transcription with E. coli RNA polymerase on the lambda cro DNA template, but at much earlier termination stop points than those recognized by E. coli Rho. Thus, the M. luteus protein functions as a true Rho factor, but with a different specificity than that of E. coli Rho. We propose that this altered specificity is consistent with its need to function on transcripts that have a high content of G + C residues.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8557681     DOI: 10.1074/jbc.271.2.742

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Modulation of DNA repair by mutations flanking the DNA channel through RNA polymerase.

Authors:  Brigitte W Trautinger; Robert G Lloyd
Journal:  EMBO J       Date:  2002-12-16       Impact factor: 11.598

2.  A high-affinity interaction between NusA and the rrn nut site in Mycobacterium tuberculosis.

Authors:  Kristine B Arnvig; S Pennell; B Gopal; M J Colston
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-24       Impact factor: 11.205

3.  The transcription termination factor Rho is essential and autoregulated in Caulobacter crescentus.

Authors:  Valéria C S Italiani; Marilis V Marques
Journal:  J Bacteriol       Date:  2005-06       Impact factor: 3.490

4.  ATP-dependent motor activity of the transcription termination factor Rho from Mycobacterium tuberculosis.

Authors:  François D'Heygère; Annie Schwartz; Franck Coste; Bertrand Castaing; Marc Boudvillain
Journal:  Nucleic Acids Res       Date:  2015-05-20       Impact factor: 16.971

Review 5.  Mastering the control of the Rho transcription factor for biotechnological applications.

Authors:  Tomás G Villa; Ana G Abril; Angeles Sánchez-Pérez
Journal:  Appl Microbiol Biotechnol       Date:  2021-05-08       Impact factor: 4.813

6.  Effects of bicyclomycin on RNA- and ATP-binding activities of transcription termination factor Rho.

Authors:  L Carrano; C Bucci; R De Pascalis; A Lavitola; F Manna; E Corti; C B Bruni; P Alifano
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

7.  Transcription termination factor Rho is essential for Micrococcus luteus.

Authors:  W L Nowatzke; E Keller; G Koch; J P Richardson
Journal:  J Bacteriol       Date:  1997-08       Impact factor: 3.490

Review 8.  Rho-dependent transcription termination: more questions than answers.

Authors:  Sharmistha Banerjee; Jisha Chalissery; Irfan Bandey; Ranjan Sen
Journal:  J Microbiol       Date:  2006-02       Impact factor: 3.422

9.  Transcription termination defective mutants of Rho: role of different functions of Rho in releasing RNA from the elongation complex.

Authors:  Jisha Chalissery; Sharmistha Banerjee; Irfan Bandey; Ranjan Sen
Journal:  J Mol Biol       Date:  2007-06-09       Impact factor: 5.469

10.  Mycobacterium tuberculosis Rho is an NTPase with distinct kinetic properties and a novel RNA-binding subdomain.

Authors:  Anirban Mitra; Rachel Misquitta; Valakunja Nagaraja
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.